1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Spinocerebellar Ataxias Global Clinical Trials Review, H2, 2015

Spinocerebellar Ataxias Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Spinocerebellar Ataxias Global Clinical Trials Review, H2, 2015" provides an overview of Spinocerebellar Ataxias clinical trials scenario. This report provides top line data relating to the clinical trials on Spinocerebellar Ataxias. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Spinocerebellar Ataxias Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Spinocerebellar Ataxias to Genetic Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Spinocerebellar Ataxias to Genetic Disorders Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Spinocerebellar Ataxias Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 47
Abbreviations 47
Definitions 47
Research Methodology 48
Secondary Research 48
About GlobalData 49
Contact Us 49
Disclaimer 49
Source 49

List of Tables
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials by Region, 2015* 6
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Spinocerebellar Ataxias Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 9
Spinocerebellar Ataxias Therapeutics Clinical Trials, Europe, Top Countries, 2015* 10
Spinocerebellar Ataxias Therapeutics Clinical Trials, North America, Top Countries, 2015* 11
Spinocerebellar Ataxias Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 12
Spinocerebellar Ataxias Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 13
Proportion of Spinocerebellar Ataxias to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 14
Spinocerebellar Ataxias Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Spinocerebellar Ataxias Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Spinocerebellar Ataxias to Genetic Disorders Clinical Trials, E7 Countries (%), 2015* 17
Spinocerebellar Ataxias Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Spinocerebellar Ataxias Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Spinocerebellar Ataxias Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 25
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

List of Figures
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Spinocerebellar Ataxias Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 9
Spinocerebellar Ataxias Therapeutics Clinical Trials, Europe, Top Countries (%), 2015* 10
Spinocerebellar Ataxias Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 13
Proportion of Spinocerebellar Ataxias to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 14
Spinocerebellar Ataxias Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Spinocerebellar Ataxias Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Spinocerebellar Ataxias to Genetic Disorders Clinical Trials, E7 Countries (%), 2015* 17
Spinocerebellar Ataxias Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Spinocerebellar Ataxias Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
Spinocerebellar Ataxias Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Spinocerebellar Ataxias Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 25
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Spinocerebellar Ataxias Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 48

Companies mentioned
Kissei Pharmaceutical Co., Ltd.
Bioblast Pharma Ltd.
Baxter International Inc.
Steminent Biotherapeutics, Inc.
Shenzhen Beike Biotechnology Co., Ltd.
Pfizer Inc.
Acorda Therapeutics, Inc.
Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul
Fundacao Amparo a Pesquisa do Estado Sao Paulo
Daiichi Sankyo Company, Limited

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Alzheimer’s disease ...

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

  • $ 3900
  • Industry report
  • November 2016
  • by Occams

"Global Multi Infarct Dementia Market Research Report 2016" by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.